Multi modal imaging in corneal edema after corneal collagen cross-linking (CXL); a case-based literature review.


Journal

BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802

Informations de publication

Date de publication:
24 Dec 2021
Historique:
received: 05 04 2021
accepted: 15 12 2021
entrez: 25 12 2021
pubmed: 26 12 2021
medline: 29 12 2021
Statut: epublish

Résumé

Keratoconus (KCN) is a common ectatic disorder of the cornea. Corneal collagen cross-linking (CXL) is used as an effective option to slowdown the disease progression. Although CXL is considered a safe procedure, corneal endothelial damage, especially in corneal thickness of less than 400 μm, has been reported. A 25-year-old man known case of KCN was referred with complaints about blurred vision and discomfort of the right eye 3 days after performing CXL. The preoperative thinnest point was 461 μm. His presenting BCVA was CF at 1 m. Examination showed central corneal edema and stromal haziness. ASOCT demonstrated increased central corneal thickness and very deep CXL line. In the confocal scan, anterior stroma showed hyper-reflective lines without recognizable cells and nerves, the middle stroma showed rare active and edematous keratocytes and a hyper-reflective reticular pattern with elongated keratocytes and needle-like structures involving the posterior stroma indicated increased depth of CXL. To manage the patient, debridement of loosened epithelium was done. Non-preservative steroid 1% eye drop was prescribed frequently. The corneal edema was completely resolved during 2 months with no need for surgical procedure and BCVA of 20/30 in his right eye. The corneal thickness of more than 400 μm cannot guarantee the absence of corneal edema after corneal collagen cross-linking, which can pertain to several factors such as inadvertently using of higher energy as well as the incorrect observance of all guidelines, instructions, and other precautions, even by a trained surgeon.

Sections du résumé

BACKGROUND BACKGROUND
Keratoconus (KCN) is a common ectatic disorder of the cornea. Corneal collagen cross-linking (CXL) is used as an effective option to slowdown the disease progression. Although CXL is considered a safe procedure, corneal endothelial damage, especially in corneal thickness of less than 400 μm, has been reported.
CASE PRESENTATION METHODS
A 25-year-old man known case of KCN was referred with complaints about blurred vision and discomfort of the right eye 3 days after performing CXL. The preoperative thinnest point was 461 μm. His presenting BCVA was CF at 1 m. Examination showed central corneal edema and stromal haziness. ASOCT demonstrated increased central corneal thickness and very deep CXL line. In the confocal scan, anterior stroma showed hyper-reflective lines without recognizable cells and nerves, the middle stroma showed rare active and edematous keratocytes and a hyper-reflective reticular pattern with elongated keratocytes and needle-like structures involving the posterior stroma indicated increased depth of CXL. To manage the patient, debridement of loosened epithelium was done. Non-preservative steroid 1% eye drop was prescribed frequently. The corneal edema was completely resolved during 2 months with no need for surgical procedure and BCVA of 20/30 in his right eye.
CONCLUSION CONCLUSIONS
The corneal thickness of more than 400 μm cannot guarantee the absence of corneal edema after corneal collagen cross-linking, which can pertain to several factors such as inadvertently using of higher energy as well as the incorrect observance of all guidelines, instructions, and other precautions, even by a trained surgeon.

Identifiants

pubmed: 34952566
doi: 10.1186/s12886-021-02220-x
pii: 10.1186/s12886-021-02220-x
pmc: PMC8710007
doi:

Substances chimiques

Cross-Linking Reagents 0
Photosensitizing Agents 0
Collagen 9007-34-5
Riboflavin TLM2976OFR

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

442

Informations de copyright

© 2021. The Author(s).

Références

Cornea. 2011 Dec;30(12):1495-8
pubmed: 22001813
Am J Ophthalmol. 2003 May;135(5):620-7
pubmed: 12719068
Cornea. 2007 May;26(4):385-9
pubmed: 17457183
Optom Vis Sci. 2014 Jul;91(7):803-9
pubmed: 24901485
J Refract Surg. 2016 Jan;32(1):41-6
pubmed: 26812713
Cornea. 2012 Oct;31(10):1197-200
pubmed: 22960648
Am J Ophthalmol. 2013 Mar;155(3):610-1
pubmed: 23394733
Am J Ophthalmol. 2012 Dec;154(6):922-926.e1
pubmed: 22959362
J Cataract Refract Surg. 2003 Sep;29(9):1786-90
pubmed: 14522302
Cornea. 2002 May;21(4):342-5
pubmed: 11973379
Cornea. 2014 Jun;33(6):630-3
pubmed: 24699560
J Cataract Refract Surg. 2010 Jan;36(1):114-20
pubmed: 20117714
J Cataract Refract Surg. 2009 Aug;35(8):1358-62
pubmed: 19631120
Ophthalmology. 2014 Feb;121(2):469-74
pubmed: 24183340

Auteurs

Mohammad Soleimani (M)

Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, 1336616351, Iran.

Zohre Ebrahimi (Z)

Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, 1336616351, Iran.

Mohammad Yazdani Moghadam (MY)

Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, 1336616351, Iran.

Mansoor Shahriari (M)

Imam Hossein Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Sara Behzadfar (S)

School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Bahareh Ramezani (B)

School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Kasra Cheraqpour (K)

Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, 1336616351, Iran. Cheraqpourk@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH